Materialise N.V. (MTLS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 170 | 205 | 232 | 256 | 267 | 257 | 275 | 278 |
| Operating profit | €m | 5 | 10 | ||||||
| Net profit | €m | -7 | 13 | -2 | 7 | 13 | 7 | 13 | 11 |
| EPS reported | € | 0.13 | 0.23 | ||||||
| Operating cashflow per share | € | 0.38 | 0.35 | ||||||
| Capex per share | € | 0.23 | 0.25 | ||||||
| FCF per share | € | 0.15 | 0.10 | ||||||
| Free cash flow | €m | 9 | 17 | ||||||
| Net debt | €m | -71 | -74 | ||||||
| Book value equity | €m | 255 | 256 | ||||||
| Book value per share | € | 4.32 | 4.39 | ||||||
| Number of shares | m | 59.07 | 58.33 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 36.35 | - | ||||||
| P/B LTM | x | 1.09 | 1.09 | ||||||
| P/S LTM | x | 1.09 | 1.01 | ||||||
| P/FCF LTM | x | 30.53 | 16.56 | ||||||
| EV/EBITDA LTM | x | 8.19 | 6.91 | ||||||
| EV/Sales LTM | x | 0.82 | 1.03 | ||||||
| Earnings Yield LTM | % | +2.75% | +2.87% | ||||||
| FCF Yield | % | +3.28% | +6.04% | ||||||
| Quality | |||||||||
| ROE | % | +2.90% | +4.13% | ||||||
| ROIC | % | +1.46% | +3.13% | ||||||
| Operating margin | % | +1.92% | +3.91% | ||||||
| Gross margin | % | +57.15% | +57.60% | ||||||
| FCF/Sales | % | +3.56% | +2.29% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -43.48% | 0.00% | ||||||
| Sales Growth YoY | % | -3.63% | +3.15% | ||||||
| Net Income Growth YoY | % | -44.82% | -1.06% | ||||||
| FCF Growth | % | +79.95% | +231.65% | ||||||
| Operating Profit Growth | % | -47.58% | +4.12% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.14 | 0.28 | ||||||
| Net Debt/EBITDA | x | -2.63 | -2.36 | ||||||
| EBIT/Net interest | x | 0.92 | 3.25 | ||||||
| Net debt/market cap | % | +22.61% | +15.42% | ||||||
| Net debt/Equity | x | -0.28 | -0.29 | ||||||
| Gross debt/equity | x | 0.26 | 0.23 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free